{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T10:35:04Z","timestamp":1790678104787,"version":"4.1.0"},"reference-count":78,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revue Neurologique"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.neurol.2018.07.005","type":"journal-article","created":{"date-parts":[[2018,9,14]],"date-time":"2018-09-14T08:35:49Z","timestamp":1536914149000},"page":"653-663","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"title":["Hyperdopaminergic behavioral spectrum in Parkinson's disease: A review"],"prefix":"10.1016","volume":"174","author":[{"given":"Matthieu","family":"B\u00e9reau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Fleury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walid","family":"Bouthour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Castrioto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eug\u00e9nie","family":"Lhomm\u00e9e","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Krack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neurol.2018.07.005_bib0005","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1002\/mds.23664","article-title":"Parkinson's disease: the quintessential neuropsychiatric disorder","volume":"26","author":"Weintraub","year":"2011","journal-title":"Mov Disord"},{"key":"10.1016\/j.neurol.2018.07.005_bib0010","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.neurol.2009.06.003","article-title":"\u00c9valuation des troubles comportementaux hyper- et hypodopaminergiques dans la maladie de Parkinson","volume":"165","author":"Ardouin","year":"2009","journal-title":"Rev Neurol (Paris)"},{"key":"10.1016\/j.neurol.2018.07.005_bib0015","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1002\/mds.26223","article-title":"International validation of a behavioral scale in Parkinson's disease without dementia","volume":"30","author":"Rieu","year":"2015","journal-title":"Mov Disord"},{"key":"10.1016\/j.neurol.2018.07.005_bib0020","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1002\/mds.27213","article-title":"Reversing dopaminergic sensitization","volume":"32","author":"Castrioto","year":"2017","journal-title":"Mov Disord"},{"key":"10.1016\/j.neurol.2018.07.005_bib0025","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1002\/mds.26731","article-title":"The hidden sister of motor fluctuations in Parkinson's disease: a review on nonmotor fluctuations","volume":"31","author":"Mart\u00ednez-Fern\u00e1ndez","year":"2016","journal-title":"Mov Disord"},{"key":"10.1016\/j.neurol.2018.07.005_bib0030","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1093\/brain\/aws078","article-title":"Subthalamic stimulation in Parkinson's disease: restoring the balance of motivated behaviours","volume":"135","author":"Lhomm\u00e9e","year":"2012","journal-title":"Brain"},{"key":"10.1016\/j.neurol.2018.07.005_bib0035","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1002\/mds.27101","article-title":"Psychostimulant effect of dopaminergic treatment and addictions in Parkinson's disease","volume":"32","author":"Delpont","year":"2017","journal-title":"Mov Disord"},{"key":"10.1016\/j.neurol.2018.07.005_bib0040","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1136\/jnnp.68.4.423","article-title":"Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies","volume":"68","author":"Giovannoni","year":"2000","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.neurol.2018.07.005_bib0045","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S1474-4422(03)00529-5","article-title":"Reviews compulsive use of dopamine replacement therapy in Parkinson's disease: reward systems gone awry?","volume":"2","author":"Lawrence","year":"2003","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurol.2018.07.005_bib0050","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S1474-4422(17)30004-2","article-title":"Impulse control disorders and levodopa-induced dyskinesias in Parkinson's disease: an update","volume":"16","author":"Voon","year":"2017","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurol.2018.07.005_bib0055","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.neuron.2009.01.031","article-title":"Addiction, dopamine: insights from Parkinson's disease","volume":"61","author":"Dagher","year":"2009","journal-title":"Neuron"},{"key":"10.1016\/j.neurol.2018.07.005_bib0060","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s40264-017-0590-6","article-title":"Dopamine agonists and impulse control disorders: a complex association","volume":"41","author":"Grall-Bronnec","year":"2018","journal-title":"Drug Saf"},{"key":"10.1016\/j.neurol.2018.07.005_bib0065","series-title":"On the move: a life","author":"Sacks","year":"2015"},{"key":"10.1016\/j.neurol.2018.07.005_bib0070","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/mds.26016","article-title":"Clinical spectrum of impulse control disorders in Parkinson's disease","volume":"30","author":"Weintraub","year":"2015","journal-title":"Mov Disord"},{"key":"10.1016\/j.neurol.2018.07.005_bib0075","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1136\/jnnp-2016-315277","article-title":"ICARUS study: prevalence and clinical features of impulse control disorders in Parkinson's disease","volume":"88","author":"Antonini","year":"2017","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.neurol.2018.07.005_bib0080","first-page":"5","article-title":"Dopamine and the biology of creativity: lessons from Parkinson's disease","volume":"5","author":"Lhomm\u00e9e","year":"2014","journal-title":"Front Neurol"},{"key":"10.1016\/j.neurol.2018.07.005_bib0085","doi-asserted-by":"crossref","first-page":"267","DOI":"10.3233\/JPD-150747","article-title":"Impact of mood and behavioral disorders on quality of life in Parkinson's disease","volume":"6","author":"Rieu","year":"2016","journal-title":"J Parkinsons Dis"},{"key":"10.1016\/j.neurol.2018.07.005_bib0090","doi-asserted-by":"crossref","first-page":"133","DOI":"10.3233\/JPD-150698","article-title":"Profile of neuropsychiatric symptoms in Parkinson's disease: surgical candidates compared to controls","volume":"6","author":"Lamberti","year":"2016","journal-title":"J Parkinsons Dis"},{"key":"10.1016\/j.neurol.2018.07.005_bib0095","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.parkreldis.2009.12.002","article-title":"Association between the dose of dopaminergic medication and the behavioral disturbances in Parkinson disease","volume":"16","author":"Lee","year":"2010","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.neurol.2018.07.005_bib0100","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1001\/archneurol.2010.65","article-title":"Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients","volume":"67","author":"Weintraub","year":"2010","journal-title":"Arch Neurol"},{"key":"10.1016\/j.neurol.2018.07.005_bib0105","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.parkreldis.2016.02.017","article-title":"The prevalence and clinical characteristics of hypersexuality in patients with Parkinson's disease following dopaminergic therapy: a systematic literature review","volume":"25","author":"Nakum","year":"2016","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.neurol.2018.07.005_bib0110","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/mds.26157","article-title":"Paraphilias and paraphilic disorders in Parkinson's disease: a systematic review of the literature","volume":"30","author":"Solla","year":"2015","journal-title":"Mov Disord"},{"key":"10.1016\/j.neurol.2018.07.005_bib0115","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1002\/mds.20757","article-title":"Compulsive eating and weight gain related to dopamine agonist use","volume":"21","author":"Nirenberg","year":"2006","journal-title":"Mov Disord"},{"key":"10.1016\/j.neurol.2018.07.005_bib0120","first-page":"5","article-title":"Compulsive buying: descriptive characteristics and psychiatric comorbidity","volume":"55","author":"Christenson","year":"1994","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.neurol.2018.07.005_bib0125","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1176\/ajp.2006.163.10.1806","article-title":"Estimated prevalence of compulsive buying behavior in the United States","volume":"163","author":"Koran","year":"2006","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.neurol.2018.07.005_bib0130","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1136\/jnnp-2012-302387","article-title":"Subthalamic nucleus stimulation and compulsive use of dopaminergic medication in Parkinson's disease","volume":"84","author":"Eusebio","year":"2013","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.neurol.2018.07.005_bib0135","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/mds.20045","article-title":"Punding in Parkinson's disease: its relation to the dopamine dysregulation syndrome","volume":"19","author":"Evans","year":"2004","journal-title":"Mov Disord"},{"key":"10.1016\/j.neurol.2018.07.005_bib0140","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1002\/mds.23508","article-title":"The prevalence and clinical characteristics of punding in Parkinson's disease","volume":"26","author":"Spencer","year":"2011","journal-title":"Mov Disord"},{"key":"10.1016\/j.neurol.2018.07.005_bib0145","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1002\/1531-8257(199909)14:5<836::AID-MDS1018>3.0.CO;2-0","article-title":"Punding on L-dopa","volume":"14","author":"Fernandez","year":"1999","journal-title":"Mov Disord"},{"key":"10.1016\/j.neurol.2018.07.005_bib0150","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1002\/mds.23016","article-title":"Excessive hoarding in Parkinson's disease","volume":"25","author":"O'Sullivan","year":"2010","journal-title":"Mov Disord"},{"key":"10.1016\/j.neurol.2018.07.005_bib0155","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1002\/mds.22571","article-title":"Validation of the questionnaire for impulsive-compulsive disorders in Parkinson's disease","volume":"24","author":"Weintraub","year":"2009","journal-title":"Mov Disord"},{"key":"10.1016\/j.neurol.2018.07.005_bib0160","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/mds.24023","article-title":"Questionnaire for impulsive-compulsive disorders in Parkinson's Disease-Rating Scale","volume":"27","author":"Weintraub","year":"2012","journal-title":"Mov Disord"},{"key":"10.1016\/j.neurol.2018.07.005_bib0165","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1002\/mdc3.12607","article-title":"The Neuropsychiatric Fluctuations Scale for Parkinson's Disease: a pilot study","volume":"5","author":"Schmitt","year":"2018","journal-title":"Mov Disord Clin Pract"},{"key":"10.1016\/j.neurol.2018.07.005_bib0170","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1002\/ana.22356","article-title":"Impulse control disorders in parkinson disease: a multicenter case-control study","volume":"69","author":"Voon","year":"2011","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurol.2018.07.005_bib0175","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/mds.25291","article-title":"Prospective cohort study of impulse control disorders in Parkinson's disease","volume":"28","author":"Bastiaens","year":"2013","journal-title":"Mov Disord"},{"key":"10.1016\/j.neurol.2018.07.005_bib0180","doi-asserted-by":"crossref","first-page":"625","DOI":"10.3233\/JPD-150535","article-title":"Apathy and impulse control disorders: yin & yang of dopamine dependent behaviors","volume":"5","author":"Sierra","year":"2015","journal-title":"J Parkinsons Dis"},{"key":"10.1016\/j.neurol.2018.07.005_bib0185","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s00702-012-0934-4","article-title":"Genetics of impulse control disorders in Parkinson's disease","volume":"120","author":"Cormier","year":"2013","journal-title":"J Neural Transm"},{"key":"10.1016\/j.neurol.2018.07.005_bib0190","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1136\/jnnp-2015-312848","article-title":"Clinical-genetic model predicts incident impulse control disorders in Parkinson's disease","volume":"87","author":"Kraemmer","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.neurol.2018.07.005_bib0195","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1212\/WNL.0000000000005816","article-title":"Longitudinal analysis of impulse control disorders in Parkinson disease","volume":"91","author":"Corvol","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2018.07.005_bib0200","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.parkreldis.2012.06.005","article-title":"Effects of dopamine agonist dose and gender on the prognosis of impulse control disorders in Parkinson's disease","volume":"18","author":"Joutsa","year":"2012","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.neurol.2018.07.005_bib0205","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/mds.26099","article-title":"Management of impulse control disorders in Parkinson's disease: controversies and future approaches","volume":"30","author":"Samuel","year":"2015","journal-title":"Mov Disord"},{"key":"10.1016\/j.neurol.2018.07.005_bib0210","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/mds.20276","article-title":"Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges","volume":"20","author":"Katzenschlager","year":"2005","journal-title":"Mov Disord"},{"key":"10.1016\/j.neurol.2018.07.005_bib0215","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1136\/jnnp-2012-302444","article-title":"Psychostimulant effect of levodopa: reversing sensitisation is possible","volume":"84","author":"Castrioto","year":"2013","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.neurol.2018.07.005_bib0220","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1474-4422(18)30035-8","article-title":"Behavioural outcomes of subthalamic stimulation and medical therapy versus medical therapy alone for Parkinson's disease with early motor complications (EARLYSTIM trial): secondary analysis of an open-label randomised trial","volume":"17","author":"Lhomm\u00e9e","year":"2018","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurol.2018.07.005_bib0225","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1002\/mds.25636","article-title":"Levodopa infusion improves impulsivity and dopamine dysregulation syndrome in Parkinson's disease","volume":"28","author":"Catal\u00e1n","year":"2013","journal-title":"Mov Disord"},{"key":"10.1016\/j.neurol.2018.07.005_bib0230","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1097\/WNF.0000000000000091","article-title":"Infusion therapies and development of impulse control disorders in advanced Parkinson disease","volume":"38","author":"Todorova","year":"2015","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.neurol.2018.07.005_bib0235","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1007\/s11910-013-0386-8","article-title":"The functional anatomy of impulse control disorders","volume":"13","author":"Probst","year":"2013","journal-title":"Curr Neurol Neurosci Rep"},{"key":"10.1016\/j.neurol.2018.07.005_bib0240","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1093\/brain\/awp054","article-title":"Increased striatal dopamine release in Parkinsonian patients with pathological gambling: a [11C] raclopride PET study","volume":"132","author":"Steeves","year":"2009","journal-title":"Brain"},{"key":"10.1016\/j.neurol.2018.07.005_bib0245","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1002\/mds.26135","article-title":"[11C]-(+)-PHNO PET imaging of dopamine D2\/3 receptors in Parkinson's disease with impulse control disorders","volume":"30","author":"Payer","year":"2015","journal-title":"Mov Disord"},{"key":"10.1016\/j.neurol.2018.07.005_bib0250","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00441-017-2771-0","article-title":"The neurobiology of impulse control disorders in Parkinson's disease: from neurotransmitters to neural networks","volume":"373","author":"Vriend","year":"2018","journal-title":"Cell Tissue Res"},{"key":"10.1016\/j.neurol.2018.07.005_bib0255","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1002\/ana.20822","article-title":"Compulsive drug use linked to sensitized ventral striatal dopamine transmission","volume":"59","author":"Evans","year":"2006","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurol.2018.07.005_bib0260","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/bs.irn.2017.04.006","article-title":"Impulse control and related disorders in Parkinson's disease","volume":"133","author":"Weintraub","year":"2017","journal-title":"Int Rev Neurobiol"},{"key":"10.1016\/j.neurol.2018.07.005_bib0265","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1093\/brain\/aws326","article-title":"Neural response to visual sexual cues in dopamine treatment-linked hypersexuality in Parkinson's disease","volume":"136","author":"Politis","year":"2013","journal-title":"Brain"},{"key":"10.1016\/j.neurol.2018.07.005_bib0270","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/S0893-133X(02)00366-4","article-title":"Amphetamine-induced increases in extracellular dopamine, drug, wanting, and novelty seeking A PET\/[11C]. Raclopride study in healthy men","volume":"27","author":"Leyton","year":"2002","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neurol.2018.07.005_bib0275","first-page":"97","article-title":"Occasional review. The pre-morbid personality of patients with Parkinson's disease","volume":"48","author":"Todes","year":"1985","journal-title":"Brain"},{"key":"10.1016\/j.neurol.2018.07.005_bib0280","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1093\/brain\/awq032","article-title":"Non-motor dopamine withdrawal syndrome after surgery for Parkinson's disease: predictors and underlying mesolimbic denervation","volume":"133","author":"Thobois","year":"2010","journal-title":"Brain"},{"key":"10.1016\/j.neurol.2018.07.005_bib0285","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1093\/brain\/aww162","article-title":"The prominent role of serotonergic degeneration in apathy, anxiety and depression in de novo Parkinson's disease","volume":"139","author":"Maillet","year":"2016","journal-title":"Brain"},{"key":"10.1016\/j.neurol.2018.07.005_bib0290","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/S1474-4422(15)00019-8","article-title":"Apathy in Parkinson's disease: clinical features, neural substrates, diagnosis, and treatment","volume":"14","author":"Pagonabarraga","year":"2015","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurol.2018.07.005_bib0295","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1136\/jnnp-2015-311827","article-title":"Incident impulse control disorder symptoms and dopamine transporter imaging in Parkinson disease","volume":"87","author":"Smith","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.neurol.2018.07.005_bib0300","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1093\/brain\/awp094","article-title":"Reward-learning and the novelty-seeking personality: a between-and within-subjects study of the effects of dopamine agonists on young parkinsons patients","volume":"132","author":"B\u00f3di","year":"2009","journal-title":"Brain"},{"key":"10.1016\/j.neurol.2018.07.005_bib0305","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1002\/mds.27065","article-title":"Personality, dopamine, and Parkinson's disease: insights from subthalamic stimulation","volume":"32","author":"Lhomm\u00e9e","year":"2017","journal-title":"Mov Disord"},{"key":"10.1016\/j.neurol.2018.07.005_bib0310","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1001\/archneurol.2009.294","article-title":"Dopamine agonist withdrawal syndrome in Parkinson disease","volume":"67","author":"Rabinak","year":"2010","journal-title":"Arch Neurol"},{"key":"10.1016\/j.neurol.2018.07.005_bib0315","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1002\/mds.21118","article-title":"Punding and dyskinesias","volume":"21","author":"Silveira-Moriyama","year":"2006","journal-title":"Mov Disord"},{"key":"10.1016\/j.neurol.2018.07.005_bib0320","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1136\/jnnp-2013-306787","article-title":"Impulse control disorder in patients with Parkinson's disease under dopamine agonist therapy: a multicentre study","volume":"85","author":"Garcia-Ruiz","year":"2014","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.neurol.2018.07.005_bib0325","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1111\/ene.13034","article-title":"A European multicentre survey of impulse control behaviours in Parkinson's disease patients treated with short- and long-acting dopamine agonists","volume":"23","author":"Rizos","year":"2016","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.neurol.2018.07.005_bib0330","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.parkreldis.2011.10.010","article-title":"Transdermal rotigotine causes impulse control disorders in patients with restless legs syndrome","volume":"18","author":"Schreglmann","year":"2012","journal-title":"Park Relat Disord"},{"key":"10.1016\/j.neurol.2018.07.005_bib0335","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1007\/s00415-018-8803-1","article-title":"Improvement of impulse control disorders associated with levodopa\u2013carbidopa intestinal gel treatment in advanced Parkinson's disease","volume":"265","author":"Catalan","year":"2018","journal-title":"J Neurol"},{"key":"10.1016\/j.neurol.2018.07.005_bib0340","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.jocn.2008.12.010","article-title":"Dopamine dysregulation syndrome, impulse control disorders and punding after deep brain stimulation surgery for Parkinson's disease","volume":"16","author":"Lim","year":"2009","journal-title":"J Clin Neurosci"},{"key":"10.1016\/j.neurol.2018.07.005_bib0345","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1002\/mds.25735","article-title":"Should impulse control disorders and dopamine dysregulation syndrome be indications for deep brain stimulation and intestinal levodopa?","volume":"28","author":"Okun","year":"2013","journal-title":"Mov Disord"},{"key":"10.1016\/j.neurol.2018.07.005_bib0350","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1002\/mds.21098","article-title":"Pathological gambling in Parkinson's disease improves on chronic subthalamic nucleus stimulation","volume":"21","author":"Ardouin","year":"2006","journal-title":"Mov Disord"},{"key":"10.1016\/j.neurol.2018.07.005_bib0355","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S1474-4422(13)70294-1","article-title":"Mood and behavioural effects of subthalamic stimulation in Parkinson's disease","volume":"13","author":"Castrioto","year":"2014","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurol.2018.07.005_bib0360","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1212\/WNL.0000000000000729","article-title":"Naltrexone for impulse control disorders in Parkinson disease. A placebo-controlled study","volume":"83","author":"Papay","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2018.07.005_bib0365","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1002\/ana.22029","article-title":"Pathological gambling in Parkinson disease is reduced by amantadine","volume":"68","author":"Thomas","year":"2010","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurol.2018.07.005_bib0370","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1002\/ana.22164","article-title":"Amantadine use associated with impulse control disorders in Parkinson disease in cross-sectional study","volume":"68","author":"Weintraub","year":"2010","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurol.2018.07.005_bib0375","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1002\/mds.23964","article-title":"Multiple impulse control disorders developing in Parkinson's disease after initiation of amantadine","volume":"27","author":"Walsh","year":"2012","journal-title":"Mov Disord"},{"key":"10.1016\/j.neurol.2018.07.005_bib0380","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1002\/mds.870130338","article-title":"Clozapine for dopaminergic-induced paraphilias in Parkinson's disease","volume":"13","author":"Fernandez","year":"1998","journal-title":"Mov Disord"},{"key":"10.1016\/j.neurol.2018.07.005_bib0385","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1002\/mds.23177","article-title":"Clozapine for medication-related pathological gambling in Parkinson disease","volume":"25","author":"Rotondo","year":"2010","journal-title":"Mov Disord"},{"key":"10.1016\/j.neurol.2018.07.005_bib0390","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1212\/WNL.0b013e3182840678","article-title":"Trial of CBT for impulse control behaviors affecting Parkinson patients and their caregivers","volume":"80","author":"Okai","year":"2013","journal-title":"Neurology"}],"container-title":["Revue Neurologique"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378718307513?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378718307513?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T05:38:53Z","timestamp":1758519533000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0035378718307513"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":78,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["S0035378718307513"],"URL":"https:\/\/doi.org\/10.1016\/j.neurol.2018.07.005","relation":{},"ISSN":["0035-3787"],"issn-type":[{"value":"0035-3787","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hyperdopaminergic behavioral spectrum in Parkinson's disease: A review","name":"articletitle","label":"Article Title"},{"value":"Revue Neurologique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurol.2018.07.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}